English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/244876
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role

AuthorsRodríguez-Otero, Paula; Mateos, Maria Victoria; Martínez-López, Joaquín; Martín-Calvo, Nerea; Hernandez, Miguel T.; Ocio, Enrique M. CSIC ORCID ; Rosiñol, Laura; Martínez, Rafael; Teruel, Ana-Isabel; Gutiérrez, Norma Carmen; Bargay, Joan; Bengoechea, Óscar; Gonzalez, Yolanda; Pérez de Oteyza, Jaime; Gironella, Mercedes; Encinas, Cristina; Martín, Jesús; Cabrera, Carmen; Palomera, Luis; Arriba, Felipe de; Cedena, Maria-Teresa; Paiva, Bruno; Puig, Noemi; Oriol, Albert; Bladé, Joan; Lahuerta, Juan José; Miguel, Jesus F. San
KeywordsEpidemiology
Risk factors
Issue Date2018
PublisherSpringer Nature
CitationLeukemia 32: 2427-2434 (2018)
AbstractAlthough survival of elderly myeloma patients has significantly improved there is still a subset of patients who, despite being fit and achieving optimal responses, will die within 2 years of diagnosis due to myeloma progression. The objective of this study was to define a scoring prognostic index to identify this group of patients. We have evaluated the outcome of 490 newly diagnosed elderly myeloma patients included in two Spanish trials (GEM2005-GEM2010). Sixty-eight patients (13.8%) died within 2 years of diagnosis (early deaths) due to myeloma progression. Our study shows that the use of simple scoring model based on 4 widely available markers (elevated LDH, ISS 3, high risk CA or >75 years) can contribute to identify up-front these patients. Moreover, unsustained response (<6 months duration) emerged as one important predictor of early myeloma-related mortality associated with a significant increase in the risk of death related to myeloma progression. The identification of these patients at high risk of early death is relevant for innovative trials aiming to maintain the depth of first response, since many of them will not receive subsequent lines of therapy.
Publisher version (URL)http://dx.doi.org/10.1038/s41375-018-0072-6
URIhttp://hdl.handle.net/10261/244876
DOIhttp://dx.doi.org/10.1038/s41375-018-0072-6
ISSN0887-6924
E-ISSN1476-5551
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.